查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1671195

基因治疗的全球市场:市场规模·占有率·趋势，产业分析 (各治疗领域·媒介类别·方法·各给药途径·各地区)，未来预测 (2025年～2034年)

Gene Therapy Market Size, Share, Trends, Industry Analysis Report: By Therapeutic Area, Vector Type, Approach, Route of Administration, and Region - Market Forecast 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 154 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，基因治疗市场预计到 2034 年将达到 272.502 亿美元。该报告对当前的市场动态提供了详细的见解，并对未来的市场成长进行了分析。

基因治疗涉及纠正或替换患者细胞中的不健康基因以治疗或预防疾病。基因工程的快速发展以及对分子生物学认知的不断加深，推动了基因治疗从实验阶段走向实际临床应用。研究人员和生物製药公司正在大力投资开发安全有效的治疗方法，而监管机构正在简化审批流程，以加速基因治疗市场的扩张。

由于杜氏肌肉营养不良症 (DMD)、镰状细胞病、血友病和囊性纤维化等遗传疾病的盛行率不断上升，对基因治疗的需求正在迅速增加。与专注于症状管理的传统治疗不同，基因疗法从基因层面针对这些疾病的根本原因。这种有针对性的方法提高了治疗效果，并有可能带来长期甚至永久的缓解。近年来，CRISPR-Cas9 和锌指核酸酶 (ZFN) 等基因编辑技术的显着进步使得基因修饰更加精确和高效。

越来越多的基因疗法监管部门批准正在推动基因治疗市场的成长。美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 等政府机构已经认识到这些治疗方法的变革潜力。这些机构加快了有前途的候选人的审批流程。 Zolgensma 治疗脊髓性肌肉萎缩症 (SMA) 和 Luxturna 治疗遗传性视网膜疾病等疗法取得了显着的临床成功，为更广泛地应用基因为基础的疗法和程序铺平了道路。

基因治疗市场：概述

基于治疗领域，肿瘤疾病领域将在 2024 年引领基因治疗市场占有率，因为肿瘤疾病的流行及其治疗对身体和心理产生重大影响。

根据载体类型，病毒部分在基因治疗市场收入占有率中处于领先地位，因为它可以有效且有效率地将基因传递到针对各种癌症、单基因疾病和传染病的目标细胞中。

北美凭藉其强大的研究基础设施、先进的医疗保健系统、大量的临床试验资金以及由 FDA 领导的支持性监管框架引领基因治疗市场，从而实现新型基因疗法的快速开发和批准。

全球主要公司包括abeona·serapyutikku，诺华AG，火花·serapyutikusuLLC，giriado·saienshizu，布里斯托尔·maiyazu·Squibb，adobaumu·baiotekunorojizu，arunairamu·famashutikaruzu，美国的·gene·tekunorojizu，apuraido·jenetikku·tekunorojizu·团体，baiojen，urutorajenikkusu等举出(举行)。

目录

第1章 简介

第2章 摘要整理

第3章 分析方法

第4章 基因治疗市场洞察

  • 基因治疗:产业概要
  • 基因治疗的市场动态
    • 促进因素和机会
      • 增加基因治疗开发的审批和投资
      • 目标疾病的传播
      • 老年人口增加
    • 阻碍因素和课题
      • 製造与物流课题
      • 治疗成本高，监管架构不明确
      • 缺乏医疗基础设施
  • 波特的五力分析
    • 供应商谈判力 (高)
    • 新加入企业的威胁 (低)
    • 买主谈判力 (中)
    • 替代产品的威胁 (低)
    • 企业间竞争 (高)
  • 大环境分析
  • COVID-19影响分析与产业趋势

第5章 基因治疗市场:各治疗领域的评估

  • 简介
  • 自体免疫疾病
  • 心血管疾病
  • 皮肤疾病
  • 血液疾病
  • 代谢障碍
  • 肌肉相关疾病
  • 肿瘤性疾病
  • 其他的治疗领域

第6章 基因治疗市场:媒介的不同种类的评估

  • 简介
  • 病毒
    • 反转录病毒载体
      • 伽马反转录病毒载体
      • 慢病毒载体
    • 腺结合病毒媒介
    • 其他的病毒载体
  • 非病毒性
    • 寡核甘酸
    • 其他的非病毒载体

第7章 按基因治疗市场:方法的评估

  • 简介
  • 遗传基因增强
  • 肿瘤溶解性病毒疗法
  • 免疫疗法
  • 其他的方法

第8章 基因治疗市场:各给药途径的评估

  • 简介
  • 关节内
  • 小脑内
  • 皮内
  • 肌肉内
  • 肿瘤内
  • 静脉内
  • 膀胱内
  • 玻璃体内
  • 视网膜下
  • 其他

第9章 基因治疗市场:各地区的评估

  • 简介
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 奥地利
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
  • 南美
    • 巴西
    • 墨西哥
  • 中东·非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国

第10章 竞争情形

  • 主要打入市场企业:分类
  • 策略性架构
  • 业者情势
  • 策略的分类
    • 事业联盟/事业合作/契约
    • 扩张/合併/收购
    • 产品开发/新销售

第11章 企业简介

  • Sangamo Biosciences
  • Voyager Therapeutics
  • Ultragenyx
  • GlaxoSmithKline
  • Gilead Sciences Inc
  • Bristol Myers Squibb
  • Novartis AG
  • Spark Therapeutics LLC
  • Bluebird Bio
Product Code: PM1084

The gene therapy market size is expected to reach USD 27,250.20 million by 2034, according to a new study by Polaris Market Research. The report "Gene Therapy Market Size, Share, Trends, Industry Analysis Report: By Therapeutic Area (Autoimmune Disorders, Cardiovascular Diseases, Dermatological Disorders, Hematological Disorders, Metabolic Disorders, Muscle-Related Diseases, Oncological Disorders, and Others), Vector Type, Approach, Route of Administration, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Gene therapy involves modifying or replacing unhealthy genes within a patient's cells to treat or prevent disease. Rapid advancements in genetic engineering, along with an increasing understanding of molecular biology, have propelled gene therapy from experimental stages to real-world clinical applications. Researchers and biopharmaceutical companies are investing heavily in developing safe and effective therapies, while regulatory bodies are streamlining approval processes to accelerate gene therapy market expansion.

The demand for gene therapy has surged due to the increasing prevalence of genetic disorders such as Duchenne muscular dystrophy (DMD), sickle cell disease, hemophilia, and cystic fibrosis. Unlike traditional treatment methods that primarily focus on symptom management, gene therapy targets the underlying cause of these diseases at the genetic level. This targeted approach enhances treatment efficacy and offers the potential for long-term or even permanent relief. In recent years, significant breakthroughs in gene-editing technologies, such as CRISPR-Cas9 and zinc finger nucleases (ZFNs), have enabled more precise and efficient gene modifications.

The rising number of regulatory approvals for gene-based treatments is propelling the gene therapy market growth. Government agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have recognized the transformative potential of these therapies. They are expediting the approval process for promising candidates. Therapies such as Zolgensma for spinal muscular atrophy (SMA) and Luxturna for inherited retinal disease have demonstrated remarkable clinical success, paving the way for broader adoption of gene-based therapies or treatments.

Gene Therapy Market Report Highlights

Based on therapeutic area, the oncological disorders segment leads the gene therapy market share in 2024 due to the prevalence of significant physical and psychological impacts of the disease and its treatment.

By vector type, the viral segment leads gene therapy market revenue share due to its effective and efficient delivering genes to the targeted cells for various cancers, monogenic and infectious diseases.

North America leads the gene therapy market due to its robust research infrastructure, advanced healthcare system, significant funding for clinical trials, and a supportive regulatory framework, particularly from the FDA, which allows for rapid development and approval of new gene therapies.

A few global key market players are Abeona Therapeutic, Novartis AG, Spark Therapeutics LLC, Gilead Sciences Inc., Bristol Myers Squibb, Adverum Biotechnologies, Alnylam Pharmaceuticals, American Gene Technologies, Applied Genetic Technologies Corporation, Biogen, and Ultragenyx.

Polaris Market Research has segmented the gene therapy market report on the basis of therapeutic area, vector type, approach, route of administration, and region:

By Type Therapeutic Area Outlook (Revenue, USD Million, 2020-2034)

  • Autoimmune Disorders
  • Cardiovascular Diseases
  • Dermatological Disorders
  • Hematological Disorders
  • Metabolic Disorders
  • Muscle-Related Diseases
  • Oncological Disorders
  • Others

By Vector Type Outlook (Revenue, USD Million, 2020-2034)

  • Viral
  • Non-Viral

By Approach Outlook (Revenue, USD Million, 2020-2034)

  • Gene Augmentation
  • Oncolytic Viral Therapy
  • Immunotherapy
  • Other Approaches

By Route of Administration Outlook (Revenue, USD Million, 2020-2034)

  • Intraarticular
  • Intracerebellar
  • Intradermal
  • Intramuscular
  • Intratumoral
  • Intravenous
  • Intravesical
  • Intravitreal
  • Subretinal
  • Others

By Regional Outlook (Revenue, USD Million, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

Chapter 1. Introduction

  • 1.1 Report Description
    • 1.1.1 Objectives of the Study
    • 1.1.2 Market Scope
    • 1.1.3 Assumptions
  • 1.2 Stakeholders

Chapter 2. Executive Summary

Chapter 3. Research Methodology

  • 3.1 Overview
    • 3.1.1 Data Mining
  • 3.2 Data Sources
    • 3.2.1 Primary Sources
    • 3.2.2 Secondary Sources

Chapter 4. Gene Therapy Market Insights

  • 4.1 Gene Therapy - Industry snapshot
  • 4.1 Gene Therapy Market Dynamics
    • 4.1.1 Drivers and Opportunities
      • 4.1.1.1 Rising Approval and Investments in Gene Therapy Development
      • 4.1.1.2 Growing Prevalence of Target Diseases
      • 4.1.1.3 Growing Geriatric Population Base
    • 4.1.2 Restraints and Challenges
      • 4.1.2.1 Manufacturing and logistics challenges
      • 4.1.2.2 High Procedure Costs and Presence of Ambiguous Regulatory Framework
      • 4.1.2.3 Lack of Healthcare Infrastructure
  • 4.2 Gene Therapy Market - Porter's Five Forces
    • 4.2.1 Bargaining Power of Suppliers (High)
    • 4.2.2 Threats of New Entrants: (Low)
    • 4.2.3 Bargaining Power of Buyers (Moderate)
    • 4.2.4 Threat of Substitute (Low)
    • 4.2.5 Rivalry among existing firms (High)
  • 4.3 Gene Therapy Market - PEST Analysis
  • 4.4 Covid-19 Impact Analysis & Industry Trends

Chapter 5. Gene Therapy Market Assessment by Therapeutic Area

  • 5.1 Introduction
  • 5.2 Autoimmune Disorders
  • 5.3 Cardiovascular Diseases
  • 5.4 Dermatological Disorders
  • 5.5 Hematological Disorders
  • 5.6 Metabolic Disorders
  • 5.7 Muscle-related Diseases
  • 5.8 Oncological Disorders
  • 5.9 Other Therapeutic Areas

Chapter 6. Gene Therapy Market Assessment by Vector Type

  • 6.1 Introduction
  • 6.2 Viral
    • 6.2.1 Retroviral vectors
      • 6.2.1.1 Gamma-retroviral vectors
      • 6.2.1.2 Lentiviral vectors
    • 6.2.2 Adeno-associated virus vectors
    • 6.2.3 Other viral vectors
  • 6.3 Non-Viral
    • 6.3.1 Oligonucleotides
    • 6.3.2 Other non-viral vectors

Chapter 7. Gene Therapy Market Assessment by Approach

  • 7.1 Introduction
  • 7.2 Gene Augmentation
  • 7.1 Oncolytic Viral Therapy
  • 7.2 Immunotherapy
  • 7.3 Other Approaches

Chapter 8. Gene Therapy Market Assessment by Route of Administration

  • 8.1 Introduction
  • 8.2 Intraarticular
  • 8.3 Intracerebellar
  • 8.4 Intradermal
  • 8.5 Intramuscular
  • 8.6 Intratumoral
  • 8.7 Intravenous
  • 8.8 Intravesical
  • 8.9 Intravitreal
  • 8.10 Subretinal
  • 8.11 Others

Chapter 9. Gene Therapy Market Assessment by Region

  • 9.1 Introduction
  • 9.2 Gene Therapy Market - North America
    • 9.2.1 Gene Therapy Market - U.S.
    • 9.2.2 Gene Therapy Market - Canada
  • 9.3 Gene Therapy Market - Europe
    • 9.3.1 Gene Therapy Market - Germany
    • 9.3.2 Gene Therapy Market - UK
    • 9.3.3 Gene Therapy Market - France
    • 9.3.4 Gene Therapy Market - Italy
    • 9.3.5 Gene Therapy Market - Spain
    • 9.3.6 Gene Therapy Market - Netherlands
    • 9.3.7 Gene Therapy Market - Austria
  • 9.4 Gene Therapy Market - Asia Pacific
    • 9.4.1 Gene Therapy Market - China
    • 9.4.2 Gene Therapy Market - India
    • 9.4.3 Gene Therapy Market - Japan
    • 9.4.4 Gene Therapy Market - South Korea
  • 9.5 Gene Therapy Market - Latin America
    • 9.5.1 Gene Therapy Market - Brazil
    • 9.5.2 Gene Therapy Market - Mexico
  • 9.6 Gene Therapy Market - Middle East & Africa
    • 9.6.1 Gene Therapy Market - Saudi Arabia
    • 9.6.2 Gene Therapy Market - UAE

Chapter 10. Competitive Landscape

  • 10.1 Key Market Players: Categorization
  • 10.2 Strategy Framework
  • 10.3 Vendor Landscape
  • 10.4 Strategies Categorization
    • 10.4.1 Partnerships/Collaborations/Agreements
    • 10.4.2 Expansions/Mergers/Acquisitions
    • 10.4.3 Product Development/New Launch

Chapter 11. Company Profiles

  • 11.1 Sangamo Biosciences
    • 11.1.1 Business Overview
    • 11.1.2 Financial Snapshot
    • 11.1.3 Products and Services
    • 11.1.4 Recent Developments
  • 11.2 Voyager Therapeutics
    • 11.2.1 Business Overview
    • 11.2.2 Financial Snapshot
    • 11.2.3 Products and Services
    • 11.2.4 Recent Developments
  • 11.3 Ultragenyx
    • 11.3.1 Business Overview
    • 11.3.2 Financial Snapshot
    • 11.3.3 Products and Services
    • 11.3.4 Recent Developments
  • 11.4 GlaxoSmithKline
    • 11.4.1 Business Overview
    • 11.4.2 Financial Snapshot
    • 11.4.3 Products and Services
    • 11.4.4 Recent Developments
  • 11.5 Gilead Sciences Inc
    • 11.5.1 Business Overview
    • 11.5.2 Financial Snapshot
    • 11.5.3 Products and Services
    • 11.5.4 Recent Developments
  • 11.6 Bristol Myers Squibb
    • 11.6.1 Business Overview
    • 11.6.2 Financial Snapshot
    • 11.6.3 Products and Services
    • 11.6.4 Recent Developments
  • 11.7 Novartis AG
    • 11.7.1 Business Overview
    • 11.7.2 Financial Snapshot
    • 11.7.3 Products and Services
    • 11.7.4 Recent Developments
  • 11.8 Spark Therapeutics LLC
    • 11.8.1 Business Overview
    • 11.8.2 Products and Services
    • 11.8.3 Recent Developments
  • 11.9 Bluebird Bio
    • 11.9.1 Business Overview
    • 11.9.2 Recent Developments
    • 11.9.3 Products and Services
    • 11.9.4 Recent Developments

List of Tables

  • Table 1 Global Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 1 Global Gene Therapy Market, by Autoimmune Disorders, 2020-2034 (USD Million)
  • Table 2 Global Gene Therapy Market, by Cardiovascular Diseases, 2020-2034 (USD Million)
  • Table 3 Global Gene Therapy Market, by Dermatological Disorders, 2020-2034 (USD Million)
  • Table 4 Global Gene Therapy Market, by Hematological Disorders, 2020-2034 (USD Million)
  • Table 5 Global Gene Therapy Market, by Metabolic Disorders, 2020-2034 (USD Million)
  • Table 6 Global Gene Therapy Market, by Muscle-related Diseases, 2020-2034 (USD Million)
  • Table 7 Global Gene Therapy Market, by Oncological Disorders, 2020-2034 (USD Million)
  • Table 8 Global Gene Therapy Market, by Other Therapeutic Areas, 2020-2034 (USD Million)
  • Table 9 Global Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 10 Global Gene Therapy Market, by Viral, 2020-2034 (USD Million)
  • Table 11 Global Gene Therapy Market, by Retroviral vectors, 2020-2034 (USD Million)
  • Table 12 Global Gene Therapy Market, by Gamma-retroviral vectors, 2020-2034 (USD Million)
  • Table 13 Global Gene Therapy Market, by Lentiviral vectors, 2020-2034 (USD Million)
  • Table 14 Global Gene Therapy Market, by Adeno-associated virus vectors, 2020-2034 (USD Million)
  • Table 15 Global Gene Therapy Market, by Other viral vectors, 2020-2034 (USD Million)
  • Table 16 Global Gene Therapy Market, by Non-Viral, 2020-2034 (USD Million)
  • Table 17 Global Gene Therapy Market, by Oligonucleotides, 2020-2034 (USD Million)
  • Table 18 Global Gene Therapy Market, by Other non-viral vectors, 2020-2034 (USD Million)
  • Table 19 Global Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 20 Global Gene Therapy Market, by Gene Augmentation, 2020-2034 (USD Million)
  • Table 21 Global Gene Therapy Market, by Oncolytic Viral Therapy, 2020-2034 (USD Million)
  • Table 22 Global Gene Therapy Market, by Immunotherapy, 2020-2034 (USD Million)
  • Table 23 Global Gene Therapy Market, by Other Approaches, 2020-2034 (USD Million)
  • Table 24 Global Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 25 Global Gene Therapy Market, by Intraarticular, 2020-2034 (USD Million)
  • Table 26 Global Gene Therapy Market, by Intracerebellar, 2020-2034 (USD Million)
  • Table 27 Global Gene Therapy Market, by Intradermal, 2020-2034 (USD Million)
  • Table 28 Global Gene Therapy Market, by Intramuscular, 2020-2034 (USD Million)
  • Table 29 Global Gene Therapy Market, by Intratumoral, 2020-2034 (USD Million)
  • Table 30 Global Gene Therapy Market, by Intravenous, 2020-2034 (USD Million)
  • Table 31 Global Gene Therapy Market, by Intravesical, 2020-2034 (USD Million)
  • Table 32 Global Gene Therapy Market, by Intravitreal, 2020-2034 (USD Million)
  • Table 33 Global Gene Therapy Market, by Subretinal, 2020-2034 (USD Million)
  • Table 34 Global Gene Therapy Market, by Others, 2020-2034 (USD Million)
  • Table 35 Gene Therapy Market Assessment, By Geography, 2020-2034 (USD Million)
  • Table 36 North America Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 37 North America Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 38 North America Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 39 North America Gene Therapy Market, By Retroviral Vector, 2020-2034 (USD Million)
  • Table 40 North America Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 41 North America Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 42 North America Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 43 U.S. Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 44 U.S. Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 45 U.S. Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 46 U.S. Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 47 U.S. Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 48 U.S. Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 49 U.S. Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 50 Canada Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 51 Canada Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 52 Canada Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 53 Canada Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 54 Canada Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 55 Canada Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 56 Canada Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 57 Europe Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 58 Europe Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 59 Europe Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 60 Europe Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 61 Europe Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 62 Europe Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 63 Europe Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 64 Germany Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 65 Germany Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 66 Germany Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 67 Germany Gene Therapy Market, By Retroviral Vector, 2020-2034 (USD Million)
  • Table 68 Germany Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 69 Germany Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 70 Germany Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 71 UK Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 72 UK Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 73 UK Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 74 UK Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 75 UK Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 76 UK Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 77 UK Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 78 France Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 79 France Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 80 France Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 81 France Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 82 France Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 83 France Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 84 France Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 85 Italy Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 86 Italy Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 87 Italy Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 88 Italy Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 89 Italy Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 90 Italy Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 91 Italy Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 92 Spain Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 93 Spain Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 94 Spain Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 95 Spain Gene Therapy Market, By Retroviral Vector, 2020-2034 (USD Million)
  • Table 96 Spain Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 97 Spain Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 98 Spain Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 99 Netherlands Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 100 Netherlands Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 101 Netherlands Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 102 Netherlands Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 103 Netherlands Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 104 Netherlands Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 105 Netherlands Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 106 Austria Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 107 Austria Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 108 Austria Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 109 Austria Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 110 Austria Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 111 Austria Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 112 Austria Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 113 Asia Pacific Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 114 Asia Pacific Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 115 Asia Pacific Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 116 Asia Pacific Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 117 Asia Pacific Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 118 Asia Pacific Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 119 Asia Pacific Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 120 China Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 121 China Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 122 China Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 123 China Gene Therapy Market, By Retroviral Vector, 2020-2034 (USD Million)
  • Table 124 China Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 125 China Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 126 China Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 127 India Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 128 India Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 129 India Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 130 India Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 131 India Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 132 India Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 133 India Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 134 Japan Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 135 Japan Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 136 Japan Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 137 Japan Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 138 Japan Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 139 Japan Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 140 Japan Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 141 South Korea Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 142 South Korea Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 143 South Korea Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 144 South Korea Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 145 South Korea Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 146 South Korea Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 147 South Korea Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 148 Latin America Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 149 Latin America Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 150 Latin America Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 151 Latin America Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 152 Latin America Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 153 Latin America Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 154 Latin America Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 155 Brazil Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 156 Brazil Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 157 Brazil Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 158 Brazil Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 159 Brazil Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 160 Brazil Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 161 Brazil Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 162 Mexico Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 163 Mexico Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 164 Mexico Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 165 Mexico Gene Therapy Market, By Retroviral Vector, 2020-2034 (USD Million)
  • Table 166 Mexico Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 167 Mexico Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 168 Mexico Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 169 Middle East & Africa Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 170 Middle East & Africa Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 171 Middle East & Africa Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 172 Middle East & Africa Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 173 Middle East & Africa Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 174 Middle East & Africa Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 175 Middle East & Africa Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 176 Saudi Arabia Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 177 Saudi Arabia Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 178 Saudi Arabia Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 179 Saudi Arabia Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 180 Saudi Arabia Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 181 Saudi Arabia Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 182 Saudi Arabia Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 183 UAE Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 184 UAE Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 185 UAE Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 186 UAE Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 187 UAE Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 188 UAE Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 189 UAE Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)

List of Figures

  • Figure 1. Executive Summary
  • Figure 2. Research Methodology: Top Down & Bottom-Up Approach
  • Figure 3. Market by Geography, 2020-2034 (USD Million)
  • Figure 6. Porter's Five Forces
  • Figure 7. PEST Analysis
  • Figure 8. Market by Therapeutic Area
  • Figure 9. Global Gene Therapy Market, By Therapeutic Area, 2024 & 2034 (USD Million)
  • Figure 10. Market by Vector Type
  • Figure 11. Global Gene Therapy Market, By Vector Type, 2024 & 2034 (USD Million)
  • Figure 12. Market by Approach
  • Figure 13. Global Gene Therapy Market, By Approach, 2024 & 2034 (USD Million)
  • Figure 14. Market by Route of Administration
  • Figure 15. Global Gene Therapy Market, By Route of Administration, 2024 & 2034 (USD Million)
  • Figure 16. Gene Therapy Market Assessment, By Geography, 2024 & 2034 (USD Million)